Clinuvel’s Mission is to provide treatment for patients who are most severely affected by light/UV and depigmentation disorders. Clinuvel develops pharmaceutical products, which belong to the family of melanocortins, to be used as prescriptive therapies.
Clinuvel Blog Posts
Today, February 28, marks Rare Disease Day: an annual event to help highlight the effects of rare diseases on individuals, families and the...
Read MoreWe've just released the first results from our vitiligo program which you can view online here. Following their release, we expect a number...
Read More
I find vitiligo to be a fascinating, yet devastating disorder: almost overnight, patients see their skin colour erode and their identity...
Read MoreClinuvel Webcasts
Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut... Watch now |
Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut... Watch now |
Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut... Watch now |
Clinuvel Spotlight
The technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology and has spent over A$20million optimising the chemistry of afamelanotide (the active ingredient in SCENESSE®) an... Read more |
